Abbott Laboratories

Abbott Laboratories

ABTยทNYSE

$87.02

-0.82%
HealthcareMedical - Devices

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Mรฉniรจre's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

At a Glance

Live Snapshot
Market Cap$151.57B
EPS3.7400
P/E Ratio23.27
Earnings Date07/16/2026
3Y-
5Y+21.0%
10Y+199.0%
3Y+39.0%
5Y+9.0%
10Y+877.0%
3Y-17.0%
5Y+127.0%
10Y-157.0%
ABT

Abbott Laboratories Cash Conversion Engine

ABT ยท NYSE
Net Income6.52B
Depreciation & Amortization3.12B
Stock-Based Compensation664.00M
Change in Working Capital-803.00M
Others65.00M
Capital Expenditures-2.17B
Free Cash Flow7.39B

Cash Flow Quality Analysis

FCF Conversion Rate

113.4%

Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.

CapEx Intensity

22.7%

Moderate capital requirements typical of many stable businesses. Healthy balance between reinvestment and cash generation.

FCF Growth Trend

+16.4%

Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.

Working Capital Impact

-$803.00M

Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.

Cash Flow Quality Insight

Exceptional cash generation: High-quality earnings converting to growing free cash flow. The company demonstrates strong pricing power, efficient operations, and disciplined capital allocation.

Abbott Laboratories Cash Flow Statement

ABT โ€ข NYSE

Abbott Laboratories Cash Flow StatementDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015Dec 2014Dec 2013Dec 2012Dec 2011Dec 2010Dec 2009Dec 2008Dec 2007Dec 2006
OPERATING ACTIVITIES
6.5B
13.4B
5.7B
6.9B
7.1B
4.5B
3.7B
2.4B
477M
1.4B
1.6B
2.3B
2.6B
6B
4.7B
4.6B
5.7B
4.7B
3.6B
1.7B
3.1B
3.2B
3.2B
3.3B
3.5B
3.3B
3B
3.3B
3B
1.4B
1.5B
1.5B
1.7B
2.8B
3B
2.6B
2.1B
1.8B
1.9B
1.6B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
293M
-1.2B
248M
314M
429M
395M
1,850.5B
968.8B
328.4B
508.7B
1B
-4.8M
-44.5M
664M
673M
644M
685M
640M
546M
519M
477M
406M
310M
292M
246M
262M
433M
383M
387.2M
366.4M
347M
46.3M
136.5M
65M
482M
126M
215M
55M
425M
247M
32M
912M
1.4B
-539M
-342M
-391M
-1,848.5B
-967.9B
-328B
-509.3B
-545M
744.5M
2.5B
(0.0)
(1.7B)
(1.5B)
(1.9B)
(1.9B)
(970M)
(930M)
(740M)
(570M)
(620M)
(631M)
(448M)
(1B)
(1.4B)
(1.8B)
(809.7M)
(0.0)
(0.0)
(0.0)
(0.0)
-803M
-9.2B
-2.5B
-1.5B
-771M
-892M
-1.3B
-148M
1.9B
-1.5B
-156M
-490M
-1.2B
-1.9B
1.1M
658.8M
-341.4M
-39.7M
-1.1B
-548.1M
9.6B
8.6B
7.3B
9.6B
10.5B
7.9B
6.1B
6.3B
5.6B
3.2B
3B
3.7B
3.3B
9.3B
9B
8.7B
7.3B
7.3B
5.2B
5.3B
INVESTING ACTIVITIES
-2.2B
-2.2B
-2.2B
-1.8B
-1.9B
-2.2B
-1.6B
-1.4B
-1.1B
-1.1B
-1.1B
-1.1B
-1.1B
-1.8B
-1.5B
-1B
-1.1B
-1.3B
-1.7B
-1.3B
-105M
(1M)
-837M
(48M)
-53M
(16M)
-122M
(48M)
-8.4B
-55M
(2.3B)
-3.3B
-580M
-1.2B
-672.5M
-9.4B
-2.4B
-250M
(0.0)
-7.9B
-167M
-169M
-159M
-185M
-173M
-83M
-103M
-131M
-210M
-2.8B
-4.9B
-1.5B
-10.1B
-12B
-5.1B
-805.9M
-249M
-923.9M
(535.6M)
-2.1B
3M
28M
43M
152M
77M
10M
21M
73M
129M
3.7B
4.1B
5.6B
7.8B
8.9B
5.6B
954.4M
16.3M
449.2M
17.8M
18.5M
18M
9M
22M
22M
26M
19M
27M
48M
35M
42M
52M
75M
21M
2.7M
1.9B
-1.9B
-6.4M
-75.1M
-33.5M
-25.7M
-2.4B
-2.3B
-3.1B
-1.7B
-2B
-2.2B
-1.8B
-1.4B
-9.6B
-248M
(406M)
-202M
-3.9B
-6.1B
(260.8M)
-12.2B
-3.7B
-2.1B
-1.1B
-11.4B
FINANCING ACTIVITIES
-497M
-1.3B
-1.2B
-3.8B
-2.3B
-403M
-718M
-238M
-117M
-522M
-2.2B
-2.2B
-1.6B
-2.4B
-77M
-866.8M
-826.3M
-1.1B
191M
-251.7M
-1.6B
-537M
-2.5B
-699M
-248M
-50M
-1.6B
-8.5B
-1.9B
13.2B
1.1B
766M
1.8B
4.4B
-4B
2.1B
3.7B
-1.2B
-544.5M
5.7B
-4.1B
-3.8B
-3.6B
-3.3B
-3.2B
-2.6B
-2.3B
-2B
-1.8B
-1.5B
-1.4B
-1.3B
-882M
-3.2B
-2.9B
-2.7B
-2.4B
-2.2B
-2B
-1.8B
-893M
-1.3B
-1.2B
-3.8B
-2.3B
-403M
-718M
-238M
-827M
-522M
-2.2B
-2.2B
-1.6B
-2.4B
-77M
-866.8M
-826.3M
-1.1B
-1.1B
-754.5M
-82M
264M
167M
167M
255M
234M
298M
271M
-1B
53M
297M
29M
-6B
1.3B
-96K
328.4M
508.7M
1B
0.0
0.0
-6.3B
-5.4B
-7.1B
-7.6B
-5.5B
-2.8B
-4.3B
-10.4B
-5.3B
11.1B
-2.2B
-2.7B
-6.7B
716.1M
-6B
-1.1B
1B
-3.5B
-2.3B
3.6B
CASH FLOW SUMMARY
71M
-96M
-23M
-122M
-70M
71M
-16M
-116M
116M
-483M
-198M
-143M
-26M
40.1M
-43M
-620.9M
118.8M
-115.2M
200.3M
74M
906M
720M
-3B
83M
3B
3B
16M
-5.6B
-9.2B
13.6B
938M
588M
-7.3B
4B
3.2B
-5.2B
4.7B
1.7B
1.9B
-2.4B
7.6B
6.9B
9.9B
9.8B
6.8B
3.9B
3.8B
9.4B
18.6B
5B
4.1B
3.5B
10.8B
6.8B
3.6B
8.8B
4.1B
2.5B
521.2M
2.9B
8.5B
7.6B
6.9B
9.9B
9.8B
6.8B
3.9B
3.8B
9.4B
18.6B
5B
4.1B
3.5B
10.8B
6.8B
3.6B
8.8B
4.1B
2.5B
521.2M
7.4B
6.4B
5.1B
7.8B
8.6B
5.7B
4.5B
4.9B
4.4B
2.1B
1.9B
2.6B
2.2B
7.5B
7.5B
7.7B
6.2B
6.1B
3.5B
4B

SEC Filings

ABT - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
10-Q

10-Q 2026 Q1

Q1

April 29, 2026
March 31, 2026
2026
8-K

8-K 2026

N/A

April 27, 2026
April 24, 2026
2026
8-K

8-K 2026

N/A

April 17, 2026
April 10, 2026
2026
8-K

8-K 2026

N/A

April 16, 2026
April 16, 2026
2026
8-K

8-K 2026

N/A

March 23, 2026
March 23, 2026
2026
DEF 14A

DEF 14A 2026

N/A

March 13, 2026
April 24, 2026
2026
8-K

8-K 2026

N/A

March 09, 2026
March 09, 2026
2026
8-K

8-K 2026

N/A

February 26, 2026
February 23, 2026
2026
10-K

10-K 2025 FY

FY

February 20, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

February 20, 2026
February 20, 2026
2026
Showing 1 to 10 of 484 filings